Literature DB >> 10938477

Imaging Tc-99m-labeled FGF-1 targeting in rats.

K R Zinn1, S Kelpke, T R Chaudhuri, T Sugg, J M Mountz, J A Thompson.   

Abstract

Recombinant human acidic fibroblast growth factor (FGF-1) was radiolabeled with (99m)Tc by the HYNIC method. The (99m)Tc-FGF-1 retained its representative molecular mass, heparin affinity, cellular binding to both low (Kd = 9.5 nM) and high (Kd = 125 pM) affinity sites, and mitogenic activity. Gamma camera imaging after intravenous dosing in rats confirmed high liver and kidney binding. Heparin significantly decreased (99m)Tc-FGF-1 liver uptake and increased urinary excretion. These studies illustrate a new method for imaging FGF-1 targeting under various conditions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10938477     DOI: 10.1016/s0969-8051(00)00090-1

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  6 in total

1.  An S116R Phosphorylation Site Mutation in Human Fibroblast Growth Factor-1 Differentially Affects Mitogenic and Glucose-Lowering Activities.

Authors:  Xue Xia; Ozan S Kumru; Sachiko I Blaber; C Russell Middaugh; Ling Li; David M Ornitz; Jae Myoung Suh; Annette R Atkins; Michael Downes; Ronald M Evans; Connie A Tenorio; Ewa Bienkiewicz; Michael Blaber
Journal:  J Pharm Sci       Date:  2016-10-20       Impact factor: 3.534

2.  Experimental support for the foldability-function tradeoff hypothesis: segregation of the folding nucleus and functional regions in fibroblast growth factor-1.

Authors:  Liam Longo; Jihun Lee; Michael Blaber
Journal:  Protein Sci       Date:  2012-11-06       Impact factor: 6.725

Review 3.  Clinical biomarkers of angiogenesis inhibition.

Authors:  Aaron P Brown; Deborah E Citrin; Kevin A Camphausen
Journal:  Cancer Metastasis Rev       Date:  2008-09       Impact factor: 9.264

4.  Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer.

Authors:  Jae Myoung Suh; Johan W Jonker; Maryam Ahmadian; Regina Goetz; Denise Lackey; Olivia Osborn; Zhifeng Huang; Weilin Liu; Eiji Yoshihara; Theo H van Dijk; Rick Havinga; Weiwei Fan; Yun-Qiang Yin; Ruth T Yu; Christopher Liddle; Annette R Atkins; Jerrold M Olefsky; Moosa Mohammadi; Michael Downes; Ronald M Evans
Journal:  Nature       Date:  2014-07-16       Impact factor: 49.962

5.  A novel fibroblast growth factor-1 ligand with reduced heparin binding protects the heart against ischemia-reperfusion injury in the presence of heparin co-administration.

Authors:  Chahua Huang; Yang Liu; Andrew Beenken; Lin Jiang; Xiang Gao; Zhifeng Huang; Anna Hsu; Garrett J Gross; Yi-Gang Wang; Moosa Mohammadi; Jo El J Schultz
Journal:  Cardiovasc Res       Date:  2017-11-01       Impact factor: 10.787

6.  Pharmacokinetic properties of 2nd-generation fibroblast growth factor-1 mutants for therapeutic application.

Authors:  Xue Xia; Joseph P Babcock; Sachiko I Blaber; Kathleen M Harper; Michael Blaber
Journal:  PLoS One       Date:  2012-11-01       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.